Healthcare industry

Infections pose an increasing risk to hospitalized patients. In collaboration with a number of partners, the Fraunhofer IGB has developed a new therapeutic approach as part of the InnateFun project. Their strategy is to improve cells’ ability to defend themselves against harmful microorganisms by acting on their immune receptors. The researchers’ work on this therapeutic approach has reached the animal model stage.

CeGat GmbH - 06/08/2020

Specific coronavirus antibody test for all

Have I perhaps already had COVID-19 in the past? This is a question many of us have been asking. Reliable tests that would provide the answer have simply not been available until now. However, the Tübingen-based biotech company CeGaT is now offering a coronavirus antibody test to anyone who wants one, thus answering this question with the highest probability currently possible. Response to the offer has been huge in the few weeks since the test…

Review article (new edition) - 08/07/2020

Immunology – at the forefront of medical progress

Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

Affimed GmbH - 01/07/2020

"Innate cell engagers" to fight cancer

In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.

Vaccine development - 02/06/2020

CureVac as a pioneer of mRNA technology – what is behind the novel COVID-19 vaccine?

All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

The NMI Reutlingen is currently tackling a major problem associated with antibody tests for the detection of COVID-19: false positive test results.

Since May 11, 2020, CeGaT offers a CE certified corona antibody test. This test determines whether a person has antibodies against the coronavirus SARS-CoV-2. People who have antibodies are assumed to have undergone a coronavirus infection and are highly likely to be immune.

Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB - 24/04/2020

A rapid pyrogen test: the human immune system as model

Every year, around 11 million people die of sepsis (blood poisoning) caused by microorganisms or microbial residues, known as pyrogens, entering the bloodstream. The smallest amounts can trigger fever. Researchers from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have developed a pyrogen test that does not require a laboratory and is not tested on animals. It is expected to be placed on the market soon.

Scientists from Heidelberg and Mannheim launch research and development task force

Company profile - 16/12/2019

Velabs Therapeutics GmbH: each droplet is a test system

Using microfluidics to detect new therapeutic antibodies is, in simple terms, the concept developed by Velabs Therapeutics GmbH. The Heidelberg-based start-up was spun out from the European Molecular Biology Laboratory (EMBL) in 2017 with the support of EMBLEM Technology Transfer GmbH. More recently, investors have provided the young company with additional funding to expand its technologies and applications.

Article - 22/10/2019

Using CAR T cells for treating cancer

After successes in the treatment of advanced blood cancers, CAR T-cell immunotherapy has become a major beacon of hope in oncology. The first therapies have received regulatory approval. Despite their success, these immunotherapies can have serious side effects. The company AVA Lifescience develops antibodies with high tumour specificity to use as the basis for effective precision-guided CAR T-cell therapies that are better tolerated by patients.

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Immatics and Celgene Corporation have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers.

Article - 01/07/2019

Microswimmers for guided drug delivery

Medicines should act as quickly as possible and ideally only at the site of disease. However, this may be difficult when the medicines are taken up via the digestive tract or the blood system. Researchers at the Max Planck Institute for Intelligent Systems in Stuttgart have now developed a biohybrid microrobot consisting of red blood cells and bacteria that can be loaded with active ingredients.

Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, today announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional antibodies against diseases with poor treatment options. Further details of the financing round were not disclosed.

Article - 11/06/2019

New pathogens in beef and cow's milk contributing to the risk of cancer

A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.

The High-Tech Gründerfonds (HTGF) and two private investors are convinced of the importance of single-cell isolation for the production of biopharmaceuticals and for genetic analysis in research and diagnostics. EUR 3 million will be invested in the further development of the technology, the expansion of the sales organization and in opening up further applications for Cytena’s single-cell printers.

Article - 05/03/2019

Vaccination against oncogenic Epstein-Barr viruses

Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.

Plant breeding - 19/11/2018

Tobacco for health

Plants can be used as biofactories to produce valuable active ingredients such as proteins, antibodies, dyes or vaccines. A project called Newcotiana aims to re-position the existent tobacco industry infrastructure. The project partners, including Prof. Dr. Holger Puchta from the Karlsruhe Institute of Technology, use modern breeding methods to develop tobacco varieties with new capabilities.

Article - 30/10/2018

Eucor – bringing the European Campus to life

Enrolling at one university and being able to use the services of a total of five universities is unique in the European Research Area. A model project called Eucor - The European Campus offers students and young scientists this opportunity at universities in the Germany-France-Switzerland border triangle, which simultaneously acts as a borderless academic area for the sciences.

Expert interview - 17/10/2018

Biologicals are becoming increasingly important to Boehringer Ingelheim

Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.

Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales.

Article - 25/04/2018

Resistance, immunity and malaria vaccination

People who have survived a malaria infection often develop immunity to the disease. International malaria research is aimed at exploiting a person's natural immunity in order to treat malaria effectively and avoid resistance to previously effective drugs. These new approaches also raise hopes that one day countries at high risk of malaria may be able to eradicate the devastating disease.

Article - 20/02/2018

New strategies against malaria

Malaria, which is a mosquito-borne disease caused by Plasmodium parasites, is still one of the worst infectious human diseases. The parasites have developed resistance against previously effective drugs and new strategies to combat malaria are urgently needed.

CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.